Metformin for PCOS: Off-Label Use, Evidence, Risks, and Benefits

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Is metformin approved for PCOS?

No. Metformin hydrochloride tablets are labeled as an adjunct to diet and exercise to improve glycemic control in adults and children 10 years and older with type 2 diabetes; the extended-release tablets are labeled for adults with type 2 diabetes only [1][3]. PCOS is not a labeled indication, so prescribing metformin for PCOS is off-label, though a 2025 review describes it as commonly prescribed for PCOS [2].

One label detail is specific to this population: because metformin may result in ovulation in some anovulatory women, the label advises that premenopausal women be told about the potential for an unintended pregnancy [1].

What do PCOS trials show for cycles, insulin and androgens?

A 2015 systematic review and meta-analysis pooled 12 randomized trials with 608 women with PCOS [4]. Adding metformin to lifestyle change, compared with lifestyle change alone or with placebo, lowered BMI by a mean 0.73 kg/m² (95% CI -1.14 to -0.32) and subcutaneous adipose tissue by 92.49 cm², and increased the number of menstrual cycles by 1.06 over 6 months (95% CI 0.30 to 1.82) [4]. It found no difference at 6 months in other anthropometric, metabolic, reproductive (including clinical and biochemical hyperandrogenism) or psychological outcomes [4]. Metformin alone, compared with lifestyle change alone, gave similar weight and BMI at 6 months, but testosterone was lower with metformin [4].

A 2025 review of metformin in PCOS summarizes the same picture: in non-pregnant women it improves insulin resistance, menstrual regularity and androgen levels, particularly in those with obesity or insulin resistance, and it may enhance fertility when combined with other treatments [2].

One randomized trial enrolled 50 women with PCOS and insulin resistance (HOMA-IR above 2.5) and/or hyperinsulinemia and gave metformin 1,500 mg per day or myo-inositol 4 g per day for 6 months [5]. Insulin sensitivity improved in both groups, BMI fell, and the menstrual cycle normalized in about 50% of the women; neither treatment significantly changed acne or hirsutism [5].

Does metformin help with weight in PCOS?

Only modestly. The 2025 review does not support it as a first-line weight-loss treatment in PCOS [2]. In the 12-trial meta-analysis, metformin alone did not lower weight or BMI more than lifestyle change alone at 6 months [4]. For scale, in the Diabetes Prevention Program, which enrolled 3,234 adults with elevated fasting and post-load glucose rather than PCOS, weight fell 2.06% with metformin versus 0.02% with placebo during the double-blind phase (P<0.001) [6][7].

Does metformin help hirsutism or acne?

The 2025 review states that metformin is not effective as a first-line treatment for clinical hyperandrogenism, including hirsutism or acne [2]. In the 50-woman trial, neither metformin nor myo-inositol significantly changed acne or hirsutism over 6 months [5]. Testosterone was lower with metformin than with lifestyle change alone in the meta-analysis [4], and in a 12-week trial of 60 women SHBG improved with both metformin and a myo-inositol/d-chiro-inositol combination (p=0.021) [8].

Does metformin improve fertility in PCOS?

Metformin may enhance fertility when combined with other treatments [2]. A trial of 160 overweight or obese women with PCOS and infertility compared 12 weeks of exenatide with 12 weeks of metformin, then treated everyone with metformin: 29.2% of the exenatide group conceived spontaneously by week 24 versus 14.7% of the metformin group (p=0.03), while total pregnancy rates by week 64 were similar (79.2% versus 76%, p=0.65) [9].

Who is most likely to benefit?

The 2025 review points to women with obesity or insulin resistance as the group with the clearest improvements in insulin resistance, cycle regularity and androgens [2]. PCOS is associated with marked insulin resistance independent of obesity, although some lean affected women have normal insulin sensitivity [10]. The 50-woman trial enrolled women with HOMA-IR above 2.5 and/or hyperinsulinemia [5].

How is metformin dosed and monitored?

The label's schedule is written for type 2 diabetes, not PCOS [1]. Immediate-release tablets start at 500 mg twice daily or 850 mg once daily with meals, increasing by 500 mg weekly or 850 mg every 2 weeks to a maximum of 2,550 mg per day in divided doses; doses above 2,000 mg may be better tolerated three times daily [1]. Extended-release tablets are swallowed whole: 500 mg once daily with the evening meal, increasing by 500 mg weekly to a maximum of 2,000 mg once daily [3]. The PCOS trial above used 1,500 mg per day [5].

Renal function: the metformin label calls for an eGFR check before treatment and at least yearly during treatment; metformin is contraindicated below 30 mL/min/1.73 m², starting is not recommended at 30 to 45, and if eGFR later falls below 45 the label says to reassess benefit and risk [1]. For iodinated contrast, the label says to stop metformin at the time of or before the procedure in patients with eGFR 30 to 60, a history of liver disease, alcoholism or heart failure, or when intra-arterial contrast is used, then re-check eGFR 48 hours later and restart only if renal function is stable [1]. The label also says to measure hematologic parameters annually and vitamin B12 every 2 to 3 years and manage any abnormalities [1].

For the available prescription product, see metformin.

What are the risks?

Gastrointestinal effects are the most common. In a US type 2 diabetes trial of immediate-release metformin up to 2,550 mg per day (141 patients on metformin, 145 on placebo), diarrhea occurred in 53% versus 12%, nausea or vomiting in 26% versus 8%, and flatulence in 12% versus 6%; diarrhea led to discontinuation in 6% [1]. In placebo-controlled trials of the extended-release tablet (781 patients), diarrhea was 10% versus 3% and nausea or vomiting 7% versus 2%, with diarrhea leading to discontinuation in 0.6% [3]. The label notes that adverse reaction rates from different trials cannot be directly compared [1][3]. A retrospective chart review of 471 patients found the frequency of any GI adverse event was similar between extended-release and immediate-release metformin, even though about 25% of the extended-release group had been switched from immediate-release because of GI side effects [11].

Lactic acidosis carries a boxed warning. Postmarketing cases resulted in death, hypothermia, hypotension and resistant bradyarrhythmias, with an often subtle onset of malaise, myalgias, respiratory distress, somnolence or abdominal pain and a laboratory picture of blood lactate above 5 mmol/L, anion gap acidosis and metformin levels generally above 5 mcg/mL [1]. The label lists renal impairment, certain drugs such as carbonic anhydrase inhibitors like topiramate, age 65 or older, radiologic contrast studies, surgery and other procedures, hypoxic states such as acute congestive heart failure, excessive alcohol intake and hepatic impairment as risk factors, and states that the postmarketing cases primarily occurred in patients with significant renal impairment [1]. If lactic acidosis is suspected, the label says to stop metformin and treat in hospital, where prompt hemodialysis is recommended [1]. The label also says to avoid metformin in patients with clinical or laboratory evidence of hepatic disease and warns against excessive alcohol intake, which potentiates metformin's effect on lactate metabolism [1].

Vitamin B12: subnormal levels occurred in about 7% of patients in 29-week label trials and appear rapidly reversible with discontinuation or B12 supplementation [1]. In the Diabetes Prevention Program Outcomes Study, low B12 (203 pg/mL or less) was 4.3% with metformin versus 2.3% with placebo at 5 years, and combined low plus borderline-low B12 (298 pg/mL or less) was 19.1% versus 9.5% at 5 years and 20.3% versus 15.6% at 13 years; the odds of deficiency rose 13% per year of metformin use (OR 1.13, 95% CI 1.06 to 1.20) [12]. A case report described a 39-year-old woman taking metformin for PCOS who developed eyelid twitching with borderline-low B12 that resolved when metformin was stopped and returned when it was restarted [13].

What about pregnancy?

The label says data in pregnant women are limited and not sufficient to determine a drug-associated risk, and that published studies have not reported a clear association between metformin and major birth defects or miscarriage; it adds that these studies cannot definitively establish the absence of risk because of small sample sizes and inconsistent comparator groups, and it notes the risks of poorly controlled diabetes in pregnancy [1]. In animal studies, fetal-concentration measurements suggested a partial placental barrier to metformin [1]. A follow-up of children born after treatment for gestational diabetes, not PCOS, found similar body-fat percentages and metabolic measures at ages 7 to 9; children exposed to metformin were larger at age 9 in one cohort [14].

Metformin or inositol for PCOS?

In the 50-woman trial, metformin 1,500 mg per day and myo-inositol 4 g per day produced similar improvements in insulin sensitivity, BMI and cycle length over 6 months [5]. A 53-woman trial found that adding myo-inositol plus d-chiro-inositol to metformin improved menstrual regularity more than metformin alone (p<0.001), with equal pregnancy rates and no statistically significant difference in other hormonal or metabolic parameters [15]. A network meta-analysis of 22 trials and 1,079 patients found the myo-inositol plus d-chiro-inositol combination was associated with greater improvement in menstrual frequency than metformin (odds ratio 14.70, 95% CI 2.31 to 93.58, a very wide interval) and lower HOMA-IR [16]. In a 12-week trial of 60 women, both metformin and the inositol combination improved HOMA-IR (p<0.001), SHBG (p=0.021), ovarian volume and menstrual regularity, with metformin slightly better on some measures [8].